Cyrus Virata is a notable inventor based in the United States. He has made significant contributions to the field of cancer treatment through his innovative work on antibody drug conjugates (ADCs). His research focuses on developing therapeutic compositions that target specific proteins associated with cancer.

Latest Patents

Cyrus Virata holds a patent for "Antibody Drug Conjugates (ADC) That Bind To FLT3 Proteins." This invention describes ADCs that specifically bind to the FLT3 protein and its variants. The FLT3 protein exhibits a distinct expression pattern in normal adult tissues but is aberrantly expressed in various cancers. Consequently, the ADCs developed by Virata provide a promising therapeutic option for cancer treatment.

Career Highlights

Throughout his career, Cyrus Virata has focused on advancing cancer therapies. His work has contributed to a better understanding of how ADCs can be utilized to target cancer cells effectively. Although he currently holds no patents, his research continues to influence the field significantly.

Collaborations

Cyrus has collaborated with talented individuals such as Nandini Rudra-Ganguly and Christine Lowe. Their combined expertise has enhanced the development of innovative cancer treatments.

Conclusion

Cyrus Virata's work in the field of antibody drug conjugates represents a significant advancement in cancer therapy. His innovative approach to targeting FLT3 proteins offers hope for improved treatment options for patients.

Profile summary based on public USPTO records.